Global Diabetic Nephropathy Market 2018-2022

TOC_LOE

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

·         Market ecosystem

·         Market characteristics

·         Market segmentation analysis

PART 05: PIPELINE ANALYSIS

·         Pipeline analysis

PART 06: MARKET SIZING

·         Market definition

·         Market sizing 2017

·         Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

·         Bargaining power of buyers

·         Bargaining power of suppliers

·         Threat of new entrants

·         Threat of substitutes

·         Threat of rivalry

·         Market condition

PART 08: MARKET SEGMENTATION BY DRUG CLASS

·         Segmentation by drug class

·         Comparison by drug class

·         ARBs – Market size and forecast 2017-2022

·         ACE inhibitors – Market size and forecast 2017-2022

·         Others – Market size and forecast 2017-2022

·         Market opportunity by drug class

PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE

·         Segmentation by type of disease

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

·         Geographical segmentation

·         Regional comparison

·         Americas – Market size and forecast 2017-2022

·         EMEA – Market size and forecast 2017-2022

·         APAC – Market size and forecast 2017-2022

·         Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

·         Market drivers

·         Market challenges

PART 14: MARKET TRENDS

·         Rise in incidence of diabetes

·         Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease

·         Multidisciplinary approach for the management of diabetic nephropathy

PART 15: VENDOR LANDSCAPE

·         Overview

·         Landscape disruption

PART 16: VENDOR ANALYSIS

·         Vendors covered

·         Vendor classification

·         Market positioning of vendors

·         AstraZeneca

·         Merck

·         Sanofi

PART 17: APPENDIX

·         List of abbreviations